Cite
HARVARD Citation
Bellmann, L. et al. (2020). A TLR7 agonist strengthens T and NK cell function during BRAF‐targeted therapy in a preclinical melanoma model. International journal of cancer. 146 (5), pp. 1409-1420. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Bellmann, L. et al. (2020). A TLR7 agonist strengthens T and NK cell function during BRAF‐targeted therapy in a preclinical melanoma model. International journal of cancer. 146 (5), pp. 1409-1420. [Online].